A half-point cut to full-year growth guidance, a third-quarter figure that missed forecasts and a run of problems in North America and China sent Reckitt's shares sharply lower on a difficult day for the FTSE 100.
Half a percentage point, five % of value
Reckitt (LSE:RKT) lowered its expectations by only a modest margin, yet the market's response was anything but modest. On Tuesday 27 October 2026 the consumer goods group, owner of brands such as Lysol, Harpic, Durex and Finish, trimmed its full-year 2026 like-for-like revenue growth guidance for Core Reckitt to 3.5%–4.5%, down from 4%–5%. Its shares closed 4.9% lower at 5,218p, making it one of the main drags on a FTSE 100 that fell 80.79 points, or 0.8%, to 10,686.54.
The cut came with a third-quarter number that disappointed. Core Reckitt net revenue reached £2.69bn, up 3.3% on a like-for-like basis. That fell short of the 3.6% the market had expected. Stripping out Russia Hygiene, which Reckitt is in the process of selling, growth was 3.9%.
Volume, price and why the mix mattered
The make-up of growth deserved as much attention as the total. Volumes rose just 0.1%, while price and mix contributed 3.2%. Put simply, almost all of the quarter's growth came from charging more or selling a richer blend of products, rather than from customers buying more units.
For consumer staples companies, that balance is closely watched. Price increases can protect revenue and margins for a period, but sustained growth generally needs volumes to contribute too. When volumes stall, investors tend to ask whether price rises are reaching their limits or whether specific operational issues are holding sales back. In Reckitt's case, the company pointed to the latter. That distinction matters: a supply bottleneck can, in principle, be fixed with investment and time, whereas a consumer pushback against higher prices tends to be harder to reverse and can linger across several reporting periods.
Three problems stood out. Temporary manufacturing capacity constraints in North America limited supply of Lysol, with improvements under way and a recovery expected in the fourth quarter. The vitamins, minerals and supplements category in China slowed. And Finish faced tougher competition in dishwashing. Chief executive Kris Licht said "temporary manufacturing constraints limited our ability to fully meet demand", framing the Lysol issue as a supply problem rather than a lack of appetite from consumers.
The regional split reflected those pressures. North America revenue fell 1.3% like for like to £649m, and Europe edged up 0.8% to £867m. Emerging Markets were the standout, rising 8.0% to £1.17bn.
What held up – and what the market looked past
Several parts of the update were more reassuring than the share price suggested. Adjusted operating margin guidance, covering Core Reckitt and Mead Johnson, was left unchanged at 24.9%–25.6%. That implies the company still expects to protect profitability even as revenue growth slows slightly. Emerging Markets are guided to grow at a high single-digit rate for the full year, and the medium-term target of 4%–5% like-for-like growth remains in place.
Segment performance was mixed rather than uniformly weak. Germ Protection revenue rose 6.0% to £892m, with Harpic growing at a double-digit rate. Intimate Wellness climbed 6.4% to £405m, with Durex up mid-single digits and Veet up double digits. Self Care grew 2.2% to £880m, while Household Care, home to Finish, fell 1.5% to £513m. Mead Johnson, the non-core infant nutrition business, grew revenue 2.7% to £549m, although its volumes dropped 5.0%.
The headline group revenue figure of £3.36bn was down 6.9% on a reported basis. That decline was mainly the result of the Essential Home disposal, which completed on 31 December 2025, so it reflects a smaller group rather than a collapse in trading. Over nine months, Core Reckitt revenue stood at £7.80bn, up 2.9% like for like.
Reckitt is also continuing to return cash. Its £500m buyback started on 5 August 2026, and about £90m had been completed by 23 October. In September it announced a North America investment programme of up to US$600m.
Why, then, the scale of the fall? Defensive consumer stocks are often valued at a premium precisely because their growth is seen as predictable. A guidance cut, even a small one, challenges that perception. Once markets begin to doubt a company's ability to hit its own forecasts, they may also question whether medium-term targets are achievable – and that can weigh on valuation more heavily than the immediate change in numbers. On £10bn of annual Core revenue, the gap between 4.5% and 4.0% growth at the midpoint of each range is 0.5 percentage points, or £50m of revenue (£10bn × 0.5% = £50m). The £10bn figure is hypothetical and is used only to show scale.
By early afternoon the shares were down 4.94% at 5,234p, broadly where they finished. The wider market offered no help: HSBC fell 5.4% after its own results, oil majors retreated, and the FTSE 100 lagged both European and US indices, even as the FTSE 250 rose 0.9%.
Key dates to watch
- Wednesday 28 October 2026 – UK Autumn Budget and US Federal Reserve rate decision
- Wednesday 28 October 2026 – Unilever Q3 trading statement, a key consumer goods comparison
- Thursday 29 October 2026 – Haleon Q3 trading statement
- Thursday 5 November 2026 – Bank of England MPC decision
- Thursday 19 November 2026 – Reckitt North America investor event at its New Jersey headquarters
The bottom line
Reckitt's 4.9% fall reflected less the size of its guidance cut than what it signalled: volumes barely moving, Lysol supply constrained, China supplements softer and Finish under competitive pressure. Against that, unchanged margin guidance, healthy Emerging Markets growth and the ongoing buyback show parts of the business performing as planned. The company has said it expects Lysol supply to recover in the fourth quarter, and the North America investor event on 19 November offers a further opportunity to explain its plans. Whether the next set of numbers confirms that recovery is likely to determine how the FTSE 100 group's revised outlook is received.
_11_16_2026_14_47_34_233787.jpg)





Please wait processing your request...